

Gary Altwerger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3474194/publications.pdf>

Version: 2024-02-01

33
papers

824
citations

430874

18
h-index

501196

28
g-index

33
all docs

33
docs citations

33
times ranked

1365
citing authors

#	ARTICLE	IF	CITATIONS
1	Single application hybrid interstitial brachytherapy for cervical cancer: An institutional approach during the COVID-19 pandemic. <i>Journal of Contemporary Brachytherapy</i> , 2022, 14, 66-71.	0.9	4
2	Randomised phase II trial of weekly ixabepilone±±biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. <i>British Journal of Cancer</i> , 2022, 126, 1695-1703.	6.4	5
3	A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. <i>Cancer</i> , 2022, 128, 1206-1218.	4.1	28
4	Financial toxicity in patients with gynecologic malignancies: a cross sectional study. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e87.	2.2	10
5	Integrated mutational landscape analysis of uterine leiomyosarcomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	48
6	Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu. <i>Gynecologic Oncology</i> , 2021, 163, 93-99.	1.4	14
7	Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. <i>Molecular Oncology</i> , 2020, 14, 645-656.	4.6	20
8	Robotic Colostomy Takedown in a Patient with Extensive Ventral Hernias and Adhesive Disease. <i>Journal of Minimally Invasive Gynecology</i> , 2020, 27, 1256-1257.	0.6	3
9	Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 118.	2.8	30
10	Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma. <i>Gynecologic Oncology</i> , 2020, 158, 769-775.	1.4	2
11	Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. <i>Scientific Reports</i> , 2020, 10, 973.	3.3	31
12	Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. <i>Oncotarget</i> , 2020, 11, 560-570.	1.8	32
13	Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22730-22736.	7.1	52
14	PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. <i>Gynecologic Oncology</i> , 2019, 155, 144-150.	1.4	28
15	Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 619-624.	7.1	49
16	Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes. <i>Gynecologic and Obstetric Investigation</i> , 2019, 84, 290-297.	1.6	27
17	PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers. <i>Gynecologic Oncology</i> , 2019, 153, 158-164.	1.4	13
18	<i>In Vitro</i> and <i>In Vivo</i> Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1003-1011.	4.1	25

#	ARTICLE	IF	CITATIONS
19	Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2018, 23, 28-33.	0.6	4
20	A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2018, 149, 585-591.	1.4	53
21	Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2449-2456.	2.5	20
22	Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4845-4853.	7.0	18
23	Novel targeted therapies in ovarian and uterine carcinosarcomas. <i>Discovery Medicine</i> , 2018, 25, 309-319.	0.5	12
24	Mechanisms of resistance to HER2-targeted therapies in HER2-amplified uterine serous carcinoma, and strategies to overcome it. <i>Discovery Medicine</i> , 2018, 26, 39-50.	0.5	17
25	SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. <i>Gynecologic Oncology</i> , 2017, 146, 179-186.	1.4	37
26	Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study. <i>Gynecologic Oncology</i> , 2017, 144, 77-82.	1.4	36
27	Polymerase β (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. <i>Gynecologic Oncology</i> , 2017, 144, 146-152.	1.4	55
28	Dual-Targeting Nanoparticles for <i>In Vivo</i> Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 323-333.	4.1	34
29	Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. <i>Gynecologic Oncology</i> , 2017, 147, 145-152.	1.4	18
30	SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. <i>Clinical Cancer Research</i> , 2017, 23, 5836-5845.	7.0	51
31	SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/neu expression.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14009-e14009.	1.6	1
32	Uterine Didelphys and Vaginal Birth After Cesarean Delivery. <i>Obstetrics and Gynecology</i> , 2015, 125, 157-159.	2.4	14
33	PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas. <i>British Journal of Cancer</i> , 2015, 113, 1020-1026.	6.4	33